Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

95.49 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 223
Open 95.49
Bid (Size) 53.99 (400)
Ask (Size) 151.64 (100)
Prev. Close 95.49
Today's Range 95.49 - 95.49
52wk Range 42.89 - 114.99
Shares Outstanding 38,297,975
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes
From Mirum Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
+22.3%
+22.3%
1 Month
-0.2%
-0.2%
3 Month
-7.1%
-7.1%
6 Month
+32.2%
+32.2%
1 Year
+112.7%
+112.7%

More News

Read More
News headline image
Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Dips After Q1 Revenue Beat and Guidance Raise, Despite Massive IPR&D Charge ↗
Via Chartmill
News headline image
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Penn Capital Unloads 1.13 Million RealReal Shares Following Massive Stock Run-Up ↗
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
News headline image
Mirum (MIRM) Q1 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
2 Under-the-Radar Biotech Stocks Worth Buying for the Long Term ↗
Via The Motley Fool
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Prediction: Buying This Biotech Stock Today Could Set You Up for Life ↗
Via The Motley Fool
News headline image
Mirum (MIRM) Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Mirum Pharma (MIRM) Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Mirum (MIRM) Q1 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position ↗
Via The Motley Fool
News headline image
Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy? ↗
Via The Motley Fool
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Small-Cap Shudder: Russell 2000’s 1.9% Slide Signals Cracks in Economic Resilience
Via MarketMinute
Topics Artificial Intelligence Economy Energy
News headline image
Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus
From Mirum Pharmaceuticals, Inc.
Via Business Wire

Frequently Asked Questions

Is Mirum Pharmaceuticals, Inc. - common stock publicly traded?
Yes, Mirum Pharmaceuticals, Inc. - common stock is publicly traded.
What exchange does Mirum Pharmaceuticals, Inc. - common stock trade on?
Mirum Pharmaceuticals, Inc. - common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Mirum Pharmaceuticals, Inc. - common stock?
The ticker symbol for Mirum Pharmaceuticals, Inc. - common stock is MIRM on the Nasdaq Stock Market
What is the current price of Mirum Pharmaceuticals, Inc. - common stock?
The current price of Mirum Pharmaceuticals, Inc. - common stock is 95.49
When was Mirum Pharmaceuticals, Inc. - common stock last traded?
The last trade of Mirum Pharmaceuticals, Inc. - common stock was at 05/18/26 04:00 PM ET
What is the market capitalization of Mirum Pharmaceuticals, Inc. - common stock?
The market capitalization of Mirum Pharmaceuticals, Inc. - common stock is 3.66B
How many shares of Mirum Pharmaceuticals, Inc. - common stock are outstanding?
Mirum Pharmaceuticals, Inc. - common stock has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.